Please sign in to follow a disease.
Fluid bolus study reveals how IV fluids impact heart and brain in low blood volume
NCT ID NCT05705115
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in 15 healthy volunteers tested how a small amount of Ringer's acetate (a common IV fluid) affects heart function and brain blood flow when blood volume is low. Participants were given the fluid during both normal and low blood volume conditions (simulated using lower body suction). The goal was to measure how long the fluid's effects last. The findings may help guide fluid therapy in hospitals.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ringer's acetate (intravenous fluid)
- What this could lead to
- If successful, this could help doctors better understand how and when to give IV fluids to patients with low blood volume, improving treatment decisions.
- What could go wrong
- This is a small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world medical situations, and the fluid's effects may be short-lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination and focused cardiac ultrasound * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol * Sex and Contraceptive/Barrier Requirements Male participants: Not applicable. Female participants: Use of adequate birth control for women of childbearing potential. * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile when sexually active. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. * Inclusion of WOCBP is possible when either: * Using at least an acceptable effective contraceptive measure (combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence). As a minimum contraception should be maintained until treatment discontinuation. or * Confirmed negative highly sensitive urine or serum pregnancy test at screening. A pregnancy test is performed at any visit before administering IMP if more than 14 days have passed since last pregnancy test. There will be no demand for post-intervention contraception. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: Medical Conditions 1. Any medical condition limiting physical exertional capacity or requiring regular medication (allergy and contraceptives excepted). 2. Pregnancy. 3. Breastfeeding. 4. History of syncope (syncope of presumed vasovagal nature with known precipitating factor excepted). 5. Any known cardiac arrhythmia. Prior/Concomitant Therapy 6. Any drug (contraceptives excepted) used on a regular basis for a chronic condition (allergy excepted).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fluid loss are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oslo University Hospital
Oslo, Oslo, 0586, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound under the collarbone may help doctors decide who needs IV fluids after trauma
- Blood test math may flag hidden risk of anesthesia danger
- Minute-by-Minute urine tracking may sharpen fluid care after heart surgery
- A pill before surgery may steady the heart and cut bleeding during sinus operations
- A simple ultrasound might replace invasive pressure monitoring
- Morning or afternoon surgery? study tests if body clock alters anesthesia safety